The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: The role of denosumab

Gynecological Endocrinology

Volumn 30, Issue 6, 2014, Pages 403-408

  Capozzi, Anna ^a   Lello, Stefano ^b   Pontecorvi, Alfredo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

Denosumab; Osteoporosis; Osteoporotic fracture; RANKL

Indexed keywords

ALENDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PLACEBO; BONE DENSITY CONSERVATION AGENT; MONOCLONAL ANTIBODY; TNFSF11 PROTEIN, HUMAN;

ARTICLE; BONE; BONE TURNOVER; CELLULITIS; CLINICAL PRACTICE; DRUG SAFETY; ERYSIPELAS; FRAGILITY FRACTURE; HUMAN; INJECTION SITE REACTION; JAW OSTEONECROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SKIN INFECTION; SPINE FRACTURE; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; METABOLISM; MOLECULARLY TARGETED THERAPY; OSTEOCLAST; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PATHOLOGY; PATHOPHYSIOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; CELLULITIS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; OSTEOCLASTS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; RANK LIGAND;

EID: 84901284693     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2014.892067     Document Type: Article

References (62)

1. Warriner AH, Saag KG. Osteoporosis diagnosis and medical treatment. Orthop Clin North Am 2013;44:125-35
2. Diab DL, Watts NB. Bisphosphonates in the treatment of osteoporosis. Endocrinol Metab Clin North Am 2012;41:487-506
3. Esbrit P, Alcaraz MJ. Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies. Biochem Pharmacol 2013;15:1417-23
4. Przedlacki J. Strontium ranelate in post-menopausal osteoporosis. Endokrynol Pol 2011;62:23-31
5. Inderjeeth CA, Chan K, Kwan K, Lai M. Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments. J Bone Miner Metab 2012;30:493-503
6. Lim V, Clarke BL. New therapeutic targets for osteoporosis: Beyond denosumab. Maturitas 2012;73:269-72
7. Sutton EE, Riche DM. Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis. Ann Pharmacother 2012; 46:1000-9
8. Yee AJ, Raje NS. Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients. Clin Interv Aging 2012; 7:331-8
9. Sinningen K, Tsourdi E, Rauner M, et al. Skeletal and extraskeletal actions of denosumab. Endocrine 2012;42:52-62
10. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999; 30;96:3540-5. (Pubitemid 29168945
11. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med (Berl) 2001;79:243-53. (Pubitemid 32646379
12. Eghbali-Fatourechi G, Khosla S, Sanyal A, et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003;111:1221-30. (Pubitemid 36519939
13. Michigami T, Ihara-Watanabe M, Yamazaki M, Ozono K. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 2001;61: 1637-44. (Pubitemid 34292599
14. Cummings SR, San Martin J, McClung MR, et al FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65
15. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study. J Bone Miner Res 1996;11:1531-8. (Pubitemid 26331009
16. Miller PD, Bolognese MA, et al Amg Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-Term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone 2008;43:222-9
17. Bouxsein ML, Delmas PD. Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: A perspective. J Bone Miner Res 2008;23:1155-67. (Pubitemid 352040171
18. Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011;96:1727-36
19. Brown JP, Roux C, Törring O, Ho PR, et al. Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res 2013;28: 746-52
20. Papapoulos S, Chapurlat R, Libanati C. Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. J Bone Miner Res 2012;27:694-701
21. Eastell R, Christiansen C, Grauer A, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 2011;3:530-7
22. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006; 17:1645-52. (Pubitemid 44477625
23. Russell RG, Watts NB, Ebetino FH. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19: 733-59
24. Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999;145:527-38. (Pubitemid 29215717
25. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial. J Bone Miner Res 2009;24: 153-61
26. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010;25: 72-81
27. Freemantle N, Satram-Hoang S, Tang ET, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: A 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 2012;23:317-26
28. McClung MR, Zanchetta JR, Libanati C, et al. Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis. J Clin Densitom 2013;16:250-6
29. Bolognese MA, Teglbjærg CS, Zanchetta JR, et al. Denosumab significantly increases DXA BMD at both trabecular and cortical sites: Results from the FREEDOM study. J Clin Densitom 2013;16: 147-53
30. Seeman E, Delmas PD, Hanley DA, et al. Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate. J Bone Miner Res 2010;25:1886-94
31. Simon JA, Recknor C, Moffett Jr. AH, et al. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: Bone density, mass, and strength of the radius, and wrist fracture. Menopause 2013;20:130-7
32. Ito M, Nishida A, Aoyagi K, et al. Effects of risedronate on trabecular microstructure and biomechanical properties in ovariectomized rat tibia. Osteoporos Int 2005;16:1042-8. (Pubitemid 41225090
33. Adami S, Libanati C, Boonen S, et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: Results from the FREEDOM Trial. J Bone Joint Surg Am 2012;94:2113-19
34. Pignolo Jr. Early or continued osteoporosis treatment during nonvertebral fracture-healing: No harm done commentary on an article by Silvano Adami, MD, PhD, et al.: ''denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: Results from the FREEDOM trial''. J Bone Joint Surg Am 2012;94:e1781-2
35. Suzuki H, Takeuchi Y. Combination or sequential treatment using PTH and anti-resorption therapies. Clin Calcium 2012;22: 415-20
36. Kishimoto H. Combination therapy for osteoporosis. Nihon Rinsho 2009;67:975-9
37. Nakamura T. Effect and role of teriparatide in the treatment of osteoporosis. Clin Calcium 2012;22:309-14
38. Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: The DATA study randomised trial. Lancet 2013;382:50-6
39. McClung MR, Lewiecki EM, Geller ML, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int 2013;24: 227-35
40. Miller PD, Wagman RB, Peacock M, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: Sixyear results of a phase 2 clinical trial. J Clin Endocrinol Metab 2011; 96:394-402
41. Watts NB, Roux C, Ferrari S, et al. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: Coincidence or causal associatioñ Osteoporos Int 2012;23:327-37
42. Barbaroux JB, Beleut M, Brisken C, et al. Epidermal receptor activator of NF-kappaB ligand controls Langerhans cells numbers and proliferation. J Immunol 2008;181:1103-8
43. Loser K, Mehling A, Loeser S, et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 2006;12:1372-9. (Pubitemid 44924495
44. Kumar V, Sinha RK. Evolution and etiopathogenesis of bisphosphonates induced osteonecrosis of the jaw. N Am J Med Sci 2013;5: 260-5
45. Van Poznak C, Estilo C. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates. Oncology (Williston Park) 2006;20: 1053-62. (Pubitemid 46940833
46. Khan AA, Sándor GK, Dore E. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009;36:478-90
47. Epstein MS, Epstein JB, Ephros HD. The effects of osteoclast modifiers on the oral cavity: A review for prescribers. Curr Opin Support Palliat Care 2012;6:337-41
48. Kyrgidis A, Toulis KA. Denosumab-related osteonecrosis of the jaws. Osteoporos Int 2011;22:369-70
49. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012;23:1341-7
50. Van Den Wyngaert T, Wouters K, Huizing MT, Vermorken JB. RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): Non bis in idem? Support Care Cancer 2011;19:2035-40
51. Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 2010;48:221-3
52. Shane E, Burr D, Ebeling PR, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-94
53. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301. (Pubitemid 40463979
54. Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012;27:2544-50
55. Bridgeman MB, Pathak R. Denosumab for the reduction of bone loss in postmenopausal osteoporosis: A review. Clin Ther 2011;33: 1547-59
56. Yonemori K, Fujiwara Y, Minami H, et al. Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases. Cancer Sci 2008;99:1237-42. (Pubitemid 351676637
57. Paparodis R, Buehring B, Pelley E, Binkley N. A case of an unusual subtrochanteric fracture in a patient receiving denosumab. Endocr Pract 2013;21:1-17
58. Dempster DW, Lambing CL, Kostenuik PJ, Grauer A. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: A review of preclinical and clinical data. Clin Ther 2012;34:521-36
59. Martin PL, Bugelski PJ. Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: Soluble targets. Br J Pharmacol 2012;166: 806-22
60. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: Different mechanisms of action and effects. Bone 2011;48:677-92
61. Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 2011;26:1829-35
62. Block GA, Bone HG, Fang L, et al. A single-Dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012;27:1471-9